Hamran, S.; Al-Rajhi, A.A.; Jasim, K.; Al-Theyab, M.A.; Elahtam, M.; Al-Hail, M.K.; Al-Fahaidi, W.; Khamis, Y.A.; Dweidri, Y.; Elzouki, A.-N.;
et al. Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis. Diseases 2025, 13, 138.
https://doi.org/10.3390/diseases13050138
AMA Style
Hamran S, Al-Rajhi AA, Jasim K, Al-Theyab MA, Elahtam M, Al-Hail MK, Al-Fahaidi W, Khamis YA, Dweidri Y, Elzouki A-N,
et al. Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis. Diseases. 2025; 13(5):138.
https://doi.org/10.3390/diseases13050138
Chicago/Turabian Style
Hamran, Shahd, Amani A. Al-Rajhi, Kawthar Jasim, Majed A. Al-Theyab, Mohamed Elahtam, Mooza K. Al-Hail, Wadha Al-Fahaidi, Yaman A. Khamis, Yara Dweidri, Abdel-Naser Elzouki,
and et al. 2025. "Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis" Diseases 13, no. 5: 138.
https://doi.org/10.3390/diseases13050138
APA Style
Hamran, S., Al-Rajhi, A. A., Jasim, K., Al-Theyab, M. A., Elahtam, M., Al-Hail, M. K., Al-Fahaidi, W., Khamis, Y. A., Dweidri, Y., Elzouki, A.-N., & Chivese, T.
(2025). Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis. Diseases, 13(5), 138.
https://doi.org/10.3390/diseases13050138
